Longboard Pharmaceuticals Inc (LBPH) Stock Price, Quote, News and Overview
NASDAQ:LBPH - Nasdaq - US54300N1037 - Common Stock - Currency: USD
LBPH Quote, Performance and Key Statistics
59.98
+0.02 (+0.03%)
The current stock price of LBPH is 59.98 USD. In the past month the price increased by 0.44%. In the past year, price increased by 1399.5%.
LBPH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 64.61 | 796.27B | ||
| JNJ | JOHNSON & JOHNSON | 15.67 | 379.48B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 16.83 | 257.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.96 | 218.96B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.29 | 209.55B | ||
| MRK | MERCK & CO. INC. | 10.21 | 196.28B | ||
| PFE | PFIZER INC | 7.12 | 125.57B | ||
| SNY | SANOFI-ADR | 11.41 | 124.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 43.18 | 100.17B | ||
| GSK | GSK PLC-SPON ADR | 8.32 | 72.88B | ||
| ZTS | ZOETIS INC | 25.11 | 66.32B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.98 | 46.47B |
Related stock screener links
About LBPH
Company Profile
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 50 full-time employees. The company went IPO on 2021-03-12. The firm is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). The company is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The firm plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The company is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The firm is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Company Info
Longboard Pharmaceuticals Inc
4275 Executive Square, Suite 950
La Jolla CALIFORNIA 92121 US
CEO: Kevin R. Lind
Employees: 50
Company Website: https://www.longboardpharma.com/
Phone: 16195929775
Longboard Pharmaceuticals Inc / LBPH FAQ
What is the stock price of Longboard Pharmaceuticals Inc today?
The current stock price of LBPH is 59.98 USD. The price increased by 0.03% in the last trading session.
What is the ticker symbol for Longboard Pharmaceuticals Inc stock?
The exchange symbol of Longboard Pharmaceuticals Inc is LBPH and it is listed on the Nasdaq exchange.
On which exchange is LBPH stock listed?
LBPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Longboard Pharmaceuticals Inc stock?
13 analysts have analysed LBPH and the average price target is 65.96 USD. This implies a price increase of 9.97% is expected in the next year compared to the current price of 59.98. Check the Longboard Pharmaceuticals Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Longboard Pharmaceuticals Inc worth?
Longboard Pharmaceuticals Inc (LBPH) has a market capitalization of 2.34B USD. This makes LBPH a Mid Cap stock.
How many employees does Longboard Pharmaceuticals Inc have?
Longboard Pharmaceuticals Inc (LBPH) currently has 50 employees.
What are the support and resistance levels for Longboard Pharmaceuticals Inc (LBPH) stock?
Longboard Pharmaceuticals Inc (LBPH) has a support level at 59.84 and a resistance level at 59.99. Check the full technical report for a detailed analysis of LBPH support and resistance levels.
Should I buy Longboard Pharmaceuticals Inc (LBPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LBPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LBPH, evaluating the profitability, health, valuation and growth aspects
- Longboard Pharmaceuticals Inc (LBPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Longboard Pharmaceuticals Inc (LBPH) Sales and EPS estimates to see what analysts future expectations are.
- Longboard Pharmaceuticals Inc (LBPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Longboard Pharmaceuticals Inc (LBPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- Longboard Pharmaceuticals Inc (LBPH) Stock Chart to make your own analysis
- Longboard Pharmaceuticals Inc (LBPH) Latest news and press-releases to stay up to date.
Does Longboard Pharmaceuticals Inc (LBPH) stock pay dividends?
LBPH does not pay a dividend.
What is the Price/Earnings (PE) ratio of Longboard Pharmaceuticals Inc (LBPH)?
Longboard Pharmaceuticals Inc (LBPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.23).
LBPH Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LBPH. When comparing the yearly performance of all stocks, LBPH is one of the better performing stocks in the market, outperforming 99.74% of all stocks.
LBPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LBPH. No worries on liquidiy or solvency for LBPH as it has an excellent financial health rating, but there are worries on the profitability.
LBPH Financial Highlights
Over the last trailing twelve months LBPH reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS increased by 7.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.7% | ||
| ROE | -27.74% | ||
| Debt/Equity | 0 |
LBPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to LBPH. The Buy consensus is the average rating of analysts ratings from 13 analysts.